Samalizumab

Source: Wikipedia, the free encyclopedia.
Samalizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD200
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6542H10086N1702O2102S46
Molar mass147687.22 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Samalizumab is a humanized monoclonal antibody designed for oncology indications.[1]

Samalizumab was developed by Alexion Pharmaceuticals.

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab" (PDF). American Medical Association.